AtriCure (ATRC) Tops Q4 EPS by 16c, provides guidance
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $48.98 +3.14%
Financial Fact:
Loss from operations: -6.29M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Loss from operations: -6.29M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
AtriCure (NASDAQ: ATRC) reported Q4 EPS of $0.06, $0.16 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $140.5 million versus the consensus estimate of $139.55 million.
GUIDANCE:
AtriCure sees FY2026 EPS of $0.09-$0.15, versus the consensus of ($0.03). AtriCure sees FY2026 revenue of $600-610 million, versus the consensus of $602 million.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
- Myriad Uranium completes acquisition of Rush Rare Metals
- UBS Upgrades Apollo Tyres (APTY:IN) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
